Contrasting Oncology Institute (NASDAQ:TOI) and Ramsay Health Care (OTCMKTS:RMYHY)

Oncology Institute (NASDAQ:TOI) and Ramsay Health Care (OTCMKTS:RMYHY) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Valuation and Earnings

This table compares Oncology Institute and Ramsay Health Care”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$502.73 million	0.99	-$60.61 million	($0.37)	-13.59
Ramsay Health Care	N/A	N/A	N/A	N/A	N/A

Ramsay Health Care has lower revenue, but higher earnings than Oncology Institute.

Risk and Volatility

Oncology Institute has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Comparatively, Ramsay Health Care has a beta of -0.09, suggesting that its share price is 109% less volatile than the S&P 500.

Profitability

This table compares Oncology Institute and Ramsay Health Care’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-7.42%	N/A	-24.68%
Ramsay Health Care	N/A	N/A	N/A

Insider and Institutional Ownership

36.9% of Oncology Institute shares are held by institutional investors. 4.4% of Oncology Institute shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Oncology Institute and Ramsay Health Care, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	1	0	4	0	2.60
Ramsay Health Care	1	1	0	0	1.50

Oncology Institute currently has a consensus price target of $7.75, indicating a potential upside of 54.08%. Given Oncology Institute’s stronger consensus rating and higher probable upside, analysts clearly believe Oncology Institute is more favorable than Ramsay Health Care.

Summary

Oncology Institute beats Ramsay Health Care on 7 of the 9 factors compared between the two stocks.

About Oncology Institute

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

About Ramsay Health Care

Ramsay Health Care Limited owns and operates hospitals. The company offers health care services to public and private patients. It operates facilities in approximately 530 locations in the Asia Pacific, the United Kingdom, France, and Nordics. Ramsay Health Care Limited was founded in 1964 and is based in Sydney, Australia.